Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
Patents for C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom (107,979)
10/2012
10/24/2012CN102753527A Cyclohexyl amide derivatives as crf receptor antagonists
10/24/2012CN102753526A Pyridinone hydroxycyclopentyl carboxamides: HIV integrase inhibitors with therapeutic applications
10/24/2012CN102753525A Process for preparing 3-[(4s)-8-bromo-1-methyl-6-(2-pyridinyl)-4h-imidazol[1,2-a][1,4]benzodiazepine-4-yl]propionic acid methyl ester or the benzene sulfonate salt thereof, and compounds useful in that process
10/24/2012CN102746327A Method for producing hydrazine compound,and production intermediates of hydrazine compound and methods of producing the intermediates
10/24/2012CN102746278A Chiral pseudonucleoside compound and its preparation method and use
10/24/2012CN102746277A Crystal-form ilaprazole sodium and preparation method thereof
10/24/2012CN102746276A Ilaprazole sodium crystal form and preparation method thereof
10/24/2012CN102746275A Crystallization-type ilaprazole sodium and preparation method thereof
10/24/2012CN102746274A Method for preparing Esomeprazole sodium salt
10/24/2012CN102746273A Esomeprazole sodium polymorph and application of esomeprazole sodium polymorph in drugs for injection
10/24/2012CN102746272A Esomeprazole sodium polymorph, preparation method and application thereof
10/24/2012CN102746224A Preparation method of 2-aryl-3,4-disubstituted isoquinolyl-1(2H)-ketone derivative
10/24/2012CN102746218A Compounds and liquid crystalline medium
10/24/2012CN102746214A Novel indoline compounds
10/24/2012CN102743769A Imaging beta-amyloid peptides and inhibition of beta-amyloid peptide aggregation
10/24/2012CN102743382A Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration
10/24/2012CN102030917B Azabenzotriazol containing ultraviolet absorber and preparation method thereof
10/24/2012CN101567425B Organic electroluminescence device, novel platinum complex compound and novel compound capable of being a ligand thereof
10/24/2012CN101253170B Compound having triazole ring structure substituted with pyridyl group and organic electroluminescent device
10/23/2012US8294007 Method of stabilization of functional nanoscale pores for device applications
10/23/2012US8293923 Indazole derivatives as modulators of interleukin-1 receptor-associated kinase
10/23/2012US8293917 Pyrazole compounds as CCR1 antagonists
10/23/2012US8293916 Diazole derivatives
10/23/2012US8293915 Compounds and compositions as channel activating protease inhibitors
10/23/2012US8293902 Quinazoline compounds
10/23/2012US8293898 Luminophores
10/23/2012US8293771 p38 MAP kinase inhibitors
10/23/2012US8293770 Pyrrolidine derivatives as NK-3 receptor antagonists
10/23/2012US8293767 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide acid addition salts as kinase inhibitors
10/23/2012US8293753 Substituted 2-carboxamide cycloamino ureas
10/23/2012US8293752 Compounds useful as Raf kinase inhibitors
10/23/2012US8293751 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
10/23/2012US8293748 p38 MAP kinase inhibitors
10/23/2012US8293747 Heterocyclic amide compounds as protein kinase inhibitors
10/23/2012US8293738 Indazole inhibitors of kinase
10/23/2012US8293732 Antibacterial quinoline derivatives
10/23/2012US8293729 Compounds, pharmaceutical composition and methods relating thereto
10/23/2012US8293139 Charge transport compositions and electronic devices made with such compositions
10/23/2012CA2672903C Heterocyclic compounds and their use in treating inflammation, angiogenesis and cancer
10/23/2012CA2566526C Naphthaline derivatives useful as histamine-3-receptor ligands
10/23/2012CA2548058C Herbicidal pyrimidines
10/23/2012CA2547243C N-aryl piperidine substituted biphenylcarboxamides
10/23/2012CA2523178C Materials and methods to potentiate cancer treatment
10/23/2012CA2488635C Antagonists of melanin concentrating hormone receptor
10/23/2012CA2441410C Compounds and method of treatment having agonist-like activity selective at alpha 2b or 2b/2c adrenergic receptors
10/18/2012WO2012142513A1 Substituted benzene compounds
10/18/2012WO2012142504A1 Aryl-or heteroaryl-substituted benzene compounds
10/18/2012WO2012142459A1 Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
10/18/2012WO2012142329A1 Compositions and therapeutic uses of ikk-related kinase epsilon and tankbinding kinase 1 inhibitors
10/18/2012WO2012142255A1 Substituted bicyclic methyl azetidines as sphingosine-1 phosphate receptors modulators
10/18/2012WO2012141554A2 Complex in which an anti-cotinine antibody is bound to a binder material of cotinine and a binding substance, and a use therefor
10/18/2012WO2012141499A1 Novel compounds for organic electronic material and organic electroluminescent device using the same
10/18/2012WO2012141228A1 Novel pyrazole derivative
10/18/2012WO2012139930A1 Pyrazolyl-pyrimidine derivatives as kinase inhibitors
10/18/2012WO2012139775A1 Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor rar-related orphan receptor-gamma (rorgamma, nr1f3) activity and for the treatment of chronic inflammatory and autoimmune diseases
10/18/2012WO2012139524A1 Cb1 receptor inhibitor with low toxicity and optical activity and preparation method and use thereof
10/18/2012WO2012139499A1 Urea compounds as well as preparation methods, intermediates and uses thereof
10/18/2012WO2012139495A1 Mineralocorticoid receptor antagonists
10/18/2012WO2012115480A3 Diaminopyrimidine derivatives and processes for the preparation thereof
10/18/2012WO2012115478A3 Diaminopyrimidine derivatives and processes for the preparation thereof
10/18/2012WO2012113850A3 (PYRIDIN-4-YL)BENZYLAMIDES AS ALLOSTERIC MODULATORS OF ALPHA 7 nAChR
10/18/2012US20120264939 Fluoride-Releasing Compositions
10/18/2012US20120264935 Synthesis of ligands for use in actinide extraction
10/18/2012US20120264801 5-membered heterocycle-based p38 kinase inhibitors
10/18/2012US20120264785 Fluoro-substituted 3,5-dicyano-4-(1H-indazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine derivatives and methods of use thereof
10/18/2012US20120264773 Organic compounds
10/18/2012US20120264770 Hsp90 inhibitors
10/18/2012US20120264761 Aminobenzoquinazolinone M1 Receptor Positive Allosteric Modulators
10/18/2012US20120264737 Heterocyclic Modulators of Lipid Synthesis
10/18/2012US20120264734 Aryl- or Heteroaryl-Substituted Benzene Compounds
10/18/2012US20120264733 Heterocyclic compound and use thereof
10/18/2012US20120264732 Phenyl bicyclic methyl azetidine derivatives as sphingosine-1 phosphate receptors modulators
10/18/2012US20120264730 Substituted bicyclic methyl azetidines as sphingosine-1 phosphate receptors modulators
10/18/2012US20120264729 Co-crystals and salts of ccr3-inhibitors
10/18/2012US20120264728 Amino-heteroaryl derivatives as hcn blockers
10/18/2012US20120264721 Analogues of cilostazol
10/18/2012US20120264704 Substituted dihydropyrazolones and use thereof as hif-prolyl-4 -hydroxylase inhibitors
10/18/2012US20120263708 Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
10/18/2012US20120263706 Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
10/18/2012US20120263679 Combinations Comprising Heterocyclic Inhibitors of MEK and Methods of Use Thereof
10/18/2012US20120263670 Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
10/18/2012US20120263659 Use of physiological cooling active ingredients, and agents containing such active ingredients
10/18/2012US20120263650 Nitroxide modified non-steroidal anti-inflammatory compounds and uses thereof in the treatment and prevention of diseases or disorders
10/18/2012US20120261650 Organic electroluminescent device
10/18/2012CA2833301A1 Substituted bicyclic methyl azetidines as sphingosine-1 phosphate receptors modulators
10/18/2012CA2832919A1 Compounds, compositions, and therapeutic uses thereof
10/18/2012CA2832846A1 Substituted benzene compounds
10/18/2012CA2832843A1 Aryl-or heteroaryl-substituted benzene compounds
10/18/2012CA2832650A1 Novel pyrazole derivative
10/17/2012EP2511274A2 Polyamine derivative
10/17/2012EP2511267A1 3-((n-acylated aminoacyl)amino)pyrazoles as inhibitors of beta-amyloid peptide production useful for the treatment of alzheimer's disease
10/17/2012EP2511263A1 Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases
10/17/2012EP2510787A1 Propenoates as fungicides
10/17/2012EP2509977A1 Novel cationic 4-aminoindoles, dye composition comprising a cationic 4-aminoindole, processes therefor and uses thereof
10/17/2012EP2509976A1 Compounds based on a triazole group that are capable of complexing at least one metallic element and coordination complex based on these compounds
10/17/2012EP2509975A1 Benzimidazole inhibitors of leukotriene production
10/17/2012EP2509974A1 Pyrazoles derivatives modulators of calcium release -activated calcium channel and methods for treatment of non- small cell lung cancer
10/17/2012EP2509973A1 Process for the preparation of imatinib and salts thereof
10/17/2012EP2509961A1 Imidazolidinedione derivatives
10/17/2012EP2509955A1 Pyrazole derivatives as modulators of calcium release -activated calcium channel
1 ... 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 ... 1080